Deep Dive Session: Commercial Considerations for Digital Pathology Assets Supporting Therapeutics

Time: 3:30 pm
day: Conference Day One

Details:

• Mapping the landscape of digital & computational pathology, key stakeholders & value drivers for pharma
• Strategic considerations for pharma: build vs buy decisions, defining value & demonstrating ROI
• Addressing reimbursement challenges, business models & real-world barriers to adoption

Speakers:

Kristine Garside Kristine Garside, PhD is Global Director Digital Health at Johnson & Johnson. Kristine spearheads the strategy for commercial digital health capabilities and impactful solid tumor Read more

Ralph Riley Ralph Riley, MBA is Global Director Precision Medicine Access and Policy Strategy at Johnson & Johnson. In his more than twenty-years at J&J he has Read more